Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Chia‐Yu Chu's publication output changed over time?
ScholarIQpublication output · 1999–2023
Output grew100% over the shown period — from 1 works in 1999 to 2 in 2023.
1
1
1
2
1
1
3
2
19992005200820102013201720212023
What are the most-cited papers on Chia‐Yu Chu?
ScholarIQmost cited works
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
Wen‐Hung Chung, Wen‐Hung Chung, Lieh-Bang Liou, C.C. Chu, Marie Lin, Hsien-Ping Huang, Yen-Ling Lin, Joung-Liang Lan, Li-Cheng Yang, Hong-shang Hong, Ming-Jing Chen, Ping-Chin Lai, Mai-Szu Wu, Chia‐Yu Chu, Kuo-Hsien Wang, Chien‐Hsiun Chen, Cathy S.J. Fann, Jer-Yuarn Wu, Yuan-Tsong Chen
Proceedings of the National Academy of Sciences. 20051,284 Citations
Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study
Sylvia H. Kardaun, Peggy Sekula, L. Valeyrie‐Allanore, Y. Liss, Chia‐Yu Chu, D. Creamer, Alexis Sidoroff, Luigi Naldi, Maja Mockenhaupt, J C Roujeau, the RegiSCAR study group
British Journal of Dermatology. 2013995 Citations
The SCFbeta -TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in Ikappa Balpha and beta -catenin and stimulates Ikappa Balpha ubiquitination in vitro
Jeffrey Winston, Peter R. Strack, Peggy Beer‐Romero, Chia‐Yu Chu, Stephen J. Elledge, J. Wade Harper
S168778273. 1999950 CitationsOPEN ACCESS
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
Emma Guttman‐Yassky, Henrique D. Teixeira, Eric L. Simpson, Kim Papp, Aileen L. Pangan, Andrew Blauvelt, Diamant Thaçi, Chia‐Yu Chu, Hyuck-Ki Hong, Norito Katoh, Amy S. Paller, Brian Calimlim, Yihua Gu, Xiaofei Hu, Meng Liu, Yang Yang, John Liu, Allan R. Tenorio, Alvina D. Chu, Alan D. Irvine
The Lancet. 2021564 Citations
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
Thomas Bieber, Eric L. Simpson, Jonathan I. Silverberg, Diamant Thaçi, C. Paul, Andrew Pink, Yoko Kataoka, Chia‐Yu Chu, Marco DiBonaventura, Ricardo Rojo, Jeremias Antinew, Ileana A. Ionita, Rodney Sinclair, Seth Forman, Jacek Zdybski, Pinaki Biswas, Bimal Malhotra, Fan Zhang, Hernán Valdez
New England Journal of Medicine. 2021462 CitationsOPEN ACCESS
Related on ScholarIQ
National Taiwan University
Institution
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
Paper
Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study
Paper
The SCFbeta -TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in Ikappa Balpha and beta -catenin and stimulates Ikappa Balpha ubiquitination in vitro
Paper
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
Paper
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
Paper